UroAlert - GU Oncology Weekly

May 07, 2026

Videos

Peer-to-Peer Clinical Conversations

Monitoring the Marrow: Hematologic Toxicity in the Treatment of Advanced Prostate Cancer "Presentation" - Daniel Childs

Daniel Childs

At the 2026 UCSF-UCLA PSMA Conference, Daniel Childs examines hematologic toxicity following lutetium therapy.

Final Analysis of Phase 3 POTOMAC Study in High-Risk NMIBC - Maria De Santis

Maria De Santis

Maria De Santis speaks with Ashish Kamat about the POTOMAC trial results presented at ESMO.

Beyond the Abstracts

ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-Label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette-Guérin (BCG) Versus BCG Alone in BCG-Naive High-Risk, Non-Muscle Invasive Bladder Cancer - Beyond the Abstract

Immune-Based Combinations in Intermediate-/Poor-Risk Patients with Non-Clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study - Beyond the Abstract

Conference Coverage

APCCC 2026: Monitoring in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

PSMA and Beyond 2026: Incorporating PSMA PETs in Registrational Trials

SES AUA 2026: Treatment of UTUC with UGN-101: Baseline Characteristics from the uTRACT Registry Study for UGN-101

EAU 2026: Real-World Efficacy of Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Survival Impact of Early Transition After 2–3 Cycles of Chemotherapy

EAU 2026: Development of a Novel 68Ga-Labeled Radiotracer Targeting Carbonic Anhydrase IX for Diagnosis of Clear Cell Renal Cell Carcinoma

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Clinical performance of the urine-based TERT promoter AbsoluteQ Digital PCR for non-invasive detection of bladder cancer.

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology - Beyond the Abstract

A systematic review and meta-analysis of clinicopathologic factors associated with adverse oncologic outcomes in bladder cancer patients undergoing radical cystectomy: Evidence from multivariable survival prediction models.

Factors influencing adherence to intravesical instillation therapies for non-muscle-invasive bladder cancer: a scoping review protocol.

Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guérin vaccine in High-Risk Bladder Cancer.

Assessing the Relationship Between Bladder Cancer cell Contractile Phenotypes and their Invasive Properties.

New Health Economic Methodology Published: Comparing Cost-Effectiveness of BLC Versus NBI Imaging Technology in Bladder Cancer

Clinical value of VI-RADS score in predicting repeat transurethral resection in primary bladder cancer: a prospective observational study.

Addressing the challenges of health economic modelling in the context of suboptimal evidence base – case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer

Urinary Extracellular Vesicles for High-Precision Bladder Cancer Subtyping and Prognosis.

Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific Mortality.

The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes.

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project.

Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer.

Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study.

Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer.

Penile & Urethral Cancers

Lymph node surgery after centralization of penile cancer care in Sweden: Extent of use and complications.

Impact of treatment volume on outcomes for patients with penile cancer at relatively low-volume centers in Japan.

Awareness and Knowledge of Penile Cancer Among University Students in Ghana.

Renal Cancer

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis.

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Early Biohumoral Detection of Acute Kidney Injury After Robotic Renal Surgery and Its Impact on Medium-Term Renal Function.

Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

Agreement of Axial T2-MRI Versus Contrast-Enhanced CT for Solid Renal Mass Active Surveillance - Beyond the Abstract

Predictors for Recurrences Within One Year Following Radical Nephrectomy for Non-metastatic Renal Cell Carcinomas.

Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World Analysis.

Development of the PREDICT-Kidney online tool to promote informed decision-making about kidney cancer follow-up care: a qualitative co-design study.

Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell Carcinoma.

Optimizing management of small renal masses: a patient-centered approach to minimize overtreatment.

When Effective Therapies Collide: Aorto-Esophageal Fistula After Thoracic Radiotherapy and Anti-VEGF TKI in a Long-Survivor with mRCC.

Metabolic syndrome and risk of kidney cancer in the United States.

Prostate Cancer

Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E.

¹⁷⁷lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer.

Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial.

Patient Preferences for Treatment of Intermediate-Risk Prostate Cancer: A Discrete Choice Experiment.

The Experiences and Perspective of Partners of Men With Prostate Cancer in Ireland: A Qualitative Descriptive Study.

Plasma Extracellular Vesicle Proteomics Nominates Candidate Biomarkers of 177Lu-PSMA-617 Outcomes in Metastatic Prostate Cancer Patients - Beyond the Abstract

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.

Outcomes of Radiotherapy With or Without Dose Escalation to Lymph Node Metastases Detected by PET PSMA or Conventional Imaging in Node-Positive Prostate Cancer: A Real-World Multicenter Propensity Score-Matched (PRIMENOD) Analysis.

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis.

Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617.

The Outcome of Immediate Adjuvant Postoperative External Beam Radiotherapy Versus Observation Alone After Radical Prostatectomy in High-Risk Prostate Cancer: A Meta Analysis.

Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance.

The role of AI in prostate cancer care: Assessing the role of chatbots versus urologists in patient communication and empathy.

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Modern proton therapy in prostate cancer: precision in practice.

Comparing Gleason Pattern 4 Measurement Approaches on Prostate Biopsy Using Machine Learning: A Proof-of-Principle Study.

Trends in Primary- and Metastasis-Directed Radiotherapy Uptake and Survival in Metastatic Prostate Cancer.

HLA Class I Expression is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.

Diet in Prostate Cancer: Promising Side Dish or Main Course?

Diagnostic and prognostic utility of PSMA-PET/CT in node-metastatic prostate cancer.

The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond.

Quantifying the Renal Impact of [177Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry.

Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care.

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

Micro-UltraSound In Cancer - Active Surveillance (MUSIC-AS): A paired, prospective, non-inferiority trial comparing micro-ultrasound and multiparametric MRI at confirmatory biopsy.

TRUQAP® (Capivasertib) Recommended by FDA Advisory Committee for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

PSA Response as a Prognostic Factor of Overall Survival in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Real-world Evidence.

Specialty differences in treatment recommendations for low-risk prostate cancer.

Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study).

Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study.

Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review - Beyond the Abstract

Inflammation and Insulin Profiles in Men Assigned to Exercise vs. Usual Care for Prostate Cancer: Results from the Active Surveillance Exercise (ASX) Randomized Controlled Trial - Beyond the Abstract

Pushing the Boundaries of SBRT in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study - Beyond the Abstract

Upper Tract Tumors

The Impact of II-look Ureteroscopy on Survival in Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study of EAU-YAU Urothelial Working Group.

Performance of Urine Fluorescence In Situ Hybridization for Diagnosis of Upper Tract Urothelial Carcinoma: A Comprehensive Review.

Clinical Trials and Emerging Therapeutic Paradigms in Upper-Tract Urothelial Carcinoma.

When urinalysis speaks first: Unexpected atypical urothelial cells revealing upper tract urothelial carcinoma.

Testicular Cancer

Survivorship after Testicular Cancer in Adolescents and Young Adults- What is Causing Death and When?

Long-Term Risk of Alcohol Use Disorder in Testicular Cancer Survivors: A National Veterans Affairs Cohort Study.

Incidence of thromboembolic events in testicular cancer patients receiving cisplatin (TESTCIS study).

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC